top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
Jun 27, 2024
Challenges in the development and registration of biosimilars
May 31, 2024
Real-world studies for drug registration: ANVISA guidelines
Nov 6, 2023
What are the challenges in ensuring access to high-cost medicines?
Oct 26, 2023
WHAT ARE THE STEPS FOR OBTAINING AUTHORIZATION FOR CLINICAL STUDIES IN BRAZIL?
Oct 9, 2023
Important circumstances for the submission of drug registration in Brazil
Aug 22, 2023
What is the purpose of registration submission guide, based on data from scientific literature?
Jul 24, 2023
Biological and biosimilar medicines - development and commercialization challenges
Jul 9, 2023
What is required to file a drug patent application?
Jan 4, 2023
Drug stability studies. Why are they important?
Apr 8, 2022
Access to post-study medicines: status in Brazil and challenges yet to be overcome.
Apr 8, 2022
Descentralized clinical studies
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page